)
Pro-Dex (PDEX) investor relations material
Pro-Dex Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Net sales for the quarter ended December 31, 2025, increased 11% year-over-year to $18.7 million, with six-month sales up 17% to $37.2 million, driven by strong growth in orthopedic and CMF device sales and next-generation handpiece shipments.
Net income for the quarter was $2.2 million, up 7% year-over-year, and $6.9 million for the six months, a 52% increase, reflecting higher sales and a significant realized gain on investment.
Gross margin for the quarter was 31%, up 1 percentage point year-over-year, while the six-month margin was 30%, down 2 points due to increased inventory and warranty charges and less favorable product mix.
Operating income rose to $3.3 million for the quarter and $6.4 million for the six months, reflecting improved sales and cost control.
Financial highlights
Orthopedic device sales rose 27% for the quarter and 43% for the six months, driven by the launch of a next-generation handpiece for the largest customer.
CMF device sales increased 69% for the quarter and 47% for the six months, while thoracic sales declined 83% and 67%, respectively.
Repair revenue declined 35% for the quarter and 30% for the six months due to fewer repairs of legacy products.
Realized a $6.8 million gain from the sale of Monogram Technologies shares following its acquisition by Zimmer Biomet, with a $3.2 million reversal of unrealized gains.
Cash and cash equivalents increased to $8.0 million at December 31, 2025, from $419,000 at June 30, 2025.
Outlook and guidance
Backlog at December 31, 2025, was $37.4 million, with $32.5 million scheduled for delivery in fiscal 2026.
Management expects continued growth in orthopedic sales for the remainder of the fiscal year and is pursuing the acquisition of a key supplier to meet demand.
A three-year contract extension with the largest customer is expected to support continued growth.
The company is focused on expanding manufacturing capacity and launching new products, including the Helios driver for CMF applications.
- Shareholders to vote on director elections, auditor, executive pay, and equity plan extension.PDEX
Proxy Filing1 Dec 2025 - Shareholders to vote on board elections, auditor ratification, and executive pay amid record growth.PDEX
Proxy Filing1 Dec 2025 - Annual meeting seeks votes on directors, auditor, pay, and equity plan extension.PDEX
Proxy Filing1 Dec 2025 - Director elections, auditor ratification, and say-on-pay vote set for November 21, 2024.PDEX
Proxy Filing1 Dec 2025 - Revenue and net income surged on strong device sales and investment gains, but margin fell.PDEX
Q1 202630 Oct 2025 - Revenue and profit surged on orthopedic product shipments, but inventory controls remain a risk.PDEX
Q2 202516 Oct 2025 - Revenue up 24% and net income quadrupled in fiscal 2025, with strong outlook for 2026.PDEX
Q4 20254 Sep 2025 - Net income rebounded to $2.5M on 25% sales growth and improved gross margin.PDEX
Q1 202513 Jun 2025 - Sales and operating income rose sharply in 2024, but net income dropped on investment losses.PDEX
Q4 202413 Jun 2025
Next Pro-Dex earnings date
Next Pro-Dex earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)